Literature DB >> 32580951

A Selective Culture Medium for Screening Ceftazidime-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa.

Mustafa Sadek1, Laurent Poirel1,2,3, Camille Tinguely1, Patrice Nordmann4,2,3,5.   

Abstract

The SuperCAZ/AVI medium was developed for screening ceftazidime-avibactam (CZA) resistance among Gram-negative bacteria (Enterobacterales and Pseudomonas aeruginosa). It was evaluated using 50 CZA-susceptible and 42 CZA-resistant Gram-negative isolates. Its sensitivity and specificity of detection were 100%. Excellent performance of the medium was also observed by testing spiked stools, with the lower limit of detection ranging from 101 to 102 CFU/ml. This screening medium provides the opportunity to detect CZA-resistant isolates regardless of their resistance mechanisms.
Copyright © 2020 Sadek et al.

Entities:  

Keywords:  Enterobacteraleszzm321990; Pseudomonas aeruginosazzm321990; avibactam; ceftazidime; screening

Mesh：

Substances：

Year:  2020        PMID： 32580951      PMCID： PMC7448628          DOI： 10.1128/JCM.00965-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium.

Authors:  Patrice Nordmann; Delphine Girlich; Laurent Poirel
Journal:  J Clin Microbiol       Date:  2012-02-22       Impact factor: 5.948

2.  Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.

Authors:  Peera Hemarajata; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

Review 3.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 4.  Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Authors:  Roopali Sharma; Tae Eun Park; Stanley Moy
Journal:  Clin Ther       Date:  2016-03-02       Impact factor: 3.393

5.  Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.

Authors:  Tommaso Giani; Alberto Antonelli; Samanta Sennati; Vincenzo Di Pilato; Adriana Chiarelli; Antonio Cannatelli; Christopher Gatsch; Francesco Luzzaro; Teresa Spanu; Stefania Stefani; Gian Maria Rossolini
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

Review 6.  Resistance to ceftazidime-avibactam and underlying mechanisms.

Authors:  Yuhang Wang; Jin Wang; Rui Wang; Yun Cai
Journal:  J Glob Antimicrob Resist       Date:  2019-12-19       Impact factor: 4.035

7.  Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.

Authors:  Linda Mueller; Amandine Masseron; Guy Prod'Hom; Tatiana Galperine; Gilbert Greub; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

8.  High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Authors:  Samuel L Aitken; Jeffrey J Tarrand; Lalitagauri M Deshpande; Frank P Tverdek; Anne L Jones; Samuel A Shelburne; Randall A Prince; Micah M Bhatti; Kenneth V I Rolston; Ronald N Jones; Mariana Castanheira; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079

9.  KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

Authors:  Laurent Poirel; Xavier Vuillemin; Mario Juhas; Amandine Masseron; Ursina Bechtel-Grosch; Simon Tiziani; Stefano Mancini; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

10.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867
View more
  6 in total

1.  KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Authors:  Vincenzo Di Pilato; Noemi Aiezza; Valentina Viaggi; Alberto Antonelli; Luigi Principe; Tommaso Giani; Francesco Luzzaro; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Rapid ResaCeftazidime-Avibactam Enterobacterales NP Test: Rapid Detection of Ceftazidime-Avibactam Susceptibility in Enterobacterales.

Authors:  Luozhu Feng; Yining Zhao; Zhuocheng Yao; Xiaodong Zhang; Shufang Zheng; Lijiang Chen; Ying Zhang; Lingbo Wang; Tieli Zhou; Jianming Cao
Journal:  J Clin Microbiol       Date:  2022-08-10       Impact factor: 11.677

3.  Selective Culture Medium for Screening of Fosfomycin Resistance in Enterobacterales.

Authors:  Patrice Nordmann; Mustafa Sadek; José Manuel Ortiz de la Rosa; Stefan Pfister; Claudine Fournier; Laurent Poirel
Journal:  J Clin Microbiol       Date:  2021-10-20       Impact factor: 11.677

4.  Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures.

Authors:  G Bianco; M Boattini; A Bondi; S Comini; T Zaccaria; R Cavallo; C Costa
Journal:  J Hosp Infect       Date:  2022-02-06       Impact factor: 8.944

5.  Implementation of Chromatic Super CAZ/AVI® medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral.

Authors:  Gabriele Bianco; Matteo Boattini; Sara Comini; Alessio Leone; Alessandro Bondi; Teresa Zaccaria; Rossana Cavallo; Cristina Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-08-06       Impact factor: 5.103

6.  A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales.

Authors:  Weiliang Zeng; Wenli Liao; Yajie Zhao; Lingbo Wang; Hongyun Shu; Huaiyu Jia; Tao Chen; Ying Zhang; Tieli Zhou; Qing Wu
Journal:  Front Microbiol       Date:  2022-07-12       Impact factor: 6.064
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.